U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H23ClN2
Molecular Weight 314.853
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLOMIPRAMINE

SMILES

CN(C)CCCN1c2ccccc2CCc3ccc(cc31)Cl

InChI

InChIKey=GDLIGKIOYRNHDA-UHFFFAOYSA-N
InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C19H23ClN2
Molecular Weight 314.853
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Clomipramine is an antidepressant drug which was approved by FDA for the treatment of Obsessive-Compulsive Disorder. The exact mechanism of its action is unknown, however it is supposed that it may exert its effect by inhibiting serotonin reuptake.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ANAFRANIL

Approved Use

Clomipramine hydrochloride capsules USP are indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD).

Launch Date

6.3089279E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
31.3 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOMIPRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
92 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOMIPRAMINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
736 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOMIPRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
23.5 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOMIPRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 35
n = 112
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: 35
Sex: M+F
Population Size: 112
Sources:
Other AEs: Dry mouth, Constipation...
Other AEs:
Dry mouth (42.9%)
Constipation (25%)
Somnolence (24.1%)
Tremor (22.3%)
Dizziness (17.9%)
Nausea (16.1%)
Sweating (13.4%)
Asthenia (9.8%)
Insomnia (8%)
Abdominal pain (3.6%)
Sources:
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Other AEs: Somnolence, Tremor...
Other AEs:
Somnolence (46%)
Tremor (33%)
Dizziness (41%)
Headache (28%)
Insomnia (11%)
Nervousness (4%)
Myoclonus (2%)
Paresthesia (2%)
Memory impairment (7%)
Anxiety (2%)
Twitching (4%)
Hypertonia (2%)
Sleep disorder (9%)
Confusion (2%)
Depersonalization (2%)
Irritability (2%)
Panic reaction (2%)
Aggressive reaction (2%)
Paresis (2%)
Sweating increased (9%)
Rash (4%)
Pruritus (2%)
Skin odor abnormal (2%)
Dry mouth (63%)
Constipation (22%)
Nausea (9%)
Dyspepsia (13%)
Diarrhea (7%)
Anorexia (22%)
Abdominal pain (13%)
Vomiting (7%)
Eructation (2%)
Ulcerative stomatitis (2%)
Fatigue (35%)
Weight increase (2%)
Flushing (7%)
Hot flushes (2%)
Chest pain (7%)
Fever (2%)
Allergy (7%)
Pain (4%)
Weight decrease (7%)
Otitis media (4%)
Asthenia (2%)
Halitosis (2%)
Postural hypotension (4%)
Palpitation (4%)
Tachycardia (2%)
Syncope (2%)
Rhinitis (7%)
Sinusitis (2%)
Coughing (4%)
Bronchospasm (7%)
Dyspnea (2%)
Laryngitis (2%)
Micturition disorder (4%)
Urinary retention (7%)
Abnormal vision (7%)
Taste perversion (4%)
Tinnitus (4%)
Anisocoria (2%)
Blepharospasm (2%)
Eye allergy (2%)
Disorder vestibular (2%)
Muscle weakness (2%)
Anemia (2%)
Sources:
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Other AEs: Somnolence, Tremor...
Other AEs:
Somnolence (54%)
Tremor (54%)
Dizziness (54%)
Headache (52%)
Insomnia (25%)
Influence on libido (21%)
Nervousness (18%)
Myoclonus (13%)
Increased appetite (11%)
Paresthesia (9%)
Memory impairment (9%)
Anxiety (9%)
Twitching (7%)
Concentration impaired (5%)
Depression (5%)
Hypertonia (4%)
Sleep disorder (4%)
Psychosomatic disease (3%)
Yawning (3%)
Confusion (3%)
Speech disorder (3%)
Dreaming abnormal (3%)
Agitation (3%)
Migraine (3%)
Depersonalization (2%)
Irritability (2%)
Emotional lability (2%)
Panic reaction (1%)
Sweating increased (29%)
Rash (8%)
Pruritus (6%)
Dermatitis (2%)
Acne (2%)
Dry skin (2%)
Urticaria (1%)
Dry mouth (84%)
Constipation (47%)
Nausea (33%)
Dyspepsia (22%)
Diarrhea (13%)
Anorexia (12%)
Abdominal pain (11%)
Vomiting (7%)
Flatulence (6%)
Tooth disorder (5%)
Gastrointestinal disorder (2%)
Dysphagia (2%)
Esophagitis (1%)
Fatigue (39%)
Weight increase (18%)
Flushing (8%)
Hot flushes (5%)
Chest pain (4%)
Fever (4%)
Allergy (3%)
Pain (3%)
Localised edema (2%)
Chills (2%)
Postural hypotension (6%)
Palpitation (4%)
Tachycardia (4%)
Pharyngitis (14%)
Rhinitis (12%)
Sinusitis (6%)
Coughing (6%)
Bronchospasm (2%)
Epistaxis (2%)
Micturition disorder (14%)
Urinary tract infection (6%)
Micturition frequency (5%)
Urinary retention (2%)
Dysuria (2%)
Cystitis (2%)
Abnormal vision (18%)
Taste perversion (8%)
Tinnitus (6%)
Lacrimation abnormal (3%)
Mydriasis (2%)
Conjunctivitis (1%)
Myalgia (13%)
Back pain (6%)
Arthralgia (3%)
Muscle weakness (1%)
Purpura (3%)
Thirst (2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Sweating 13.4%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 35
n = 112
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: 35
Sex: M+F
Population Size: 112
Sources:
Nausea 16.1%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 35
n = 112
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: 35
Sex: M+F
Population Size: 112
Sources:
Dizziness 17.9%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 35
n = 112
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: 35
Sex: M+F
Population Size: 112
Sources:
Tremor 22.3%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 35
n = 112
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: 35
Sex: M+F
Population Size: 112
Sources:
Somnolence 24.1%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 35
n = 112
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: 35
Sex: M+F
Population Size: 112
Sources:
Constipation 25%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 35
n = 112
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: 35
Sex: M+F
Population Size: 112
Sources:
Abdominal pain 3.6%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 35
n = 112
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: 35
Sex: M+F
Population Size: 112
Sources:
Dry mouth 42.9%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 35
n = 112
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: 35
Sex: M+F
Population Size: 112
Sources:
Insomnia 8%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 35
n = 112
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: 35
Sex: M+F
Population Size: 112
Sources:
Asthenia 9.8%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 35
n = 112
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: 35
Sex: M+F
Population Size: 112
Sources:
Insomnia 11%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Abdominal pain 13%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Dyspepsia 13%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Aggressive reaction 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Anemia 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Anisocoria 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Anxiety 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Asthenia 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Blepharospasm 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Confusion 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Depersonalization 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Disorder vestibular 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Dyspnea 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Eructation 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Eye allergy 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Fever 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Halitosis 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Hot flushes 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Hypertonia 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Irritability 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Laryngitis 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Muscle weakness 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Myoclonus 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Panic reaction 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Paresis 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Paresthesia 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Pruritus 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Sinusitis 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Skin odor abnormal 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Syncope 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Tachycardia 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Ulcerative stomatitis 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Weight increase 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Anorexia 22%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Constipation 22%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Headache 28%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Tremor 33%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Fatigue 35%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Coughing 4%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Micturition disorder 4%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Nervousness 4%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Otitis media 4%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Pain 4%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Palpitation 4%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Postural hypotension 4%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Rash 4%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Taste perversion 4%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Tinnitus 4%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Twitching 4%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Dizziness 41%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Somnolence 46%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Dry mouth 63%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Abnormal vision 7%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Allergy 7%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Bronchospasm 7%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Chest pain 7%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Diarrhea 7%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Flushing 7%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Memory impairment 7%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Rhinitis 7%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Urinary retention 7%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Vomiting 7%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Weight decrease 7%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Nausea 9%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Sleep disorder 9%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Sweating increased 9%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Conjunctivitis 1%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Esophagitis 1%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Muscle weakness 1%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Panic reaction 1%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Urticaria 1%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Abdominal pain 11%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Increased appetite 11%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Anorexia 12%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Rhinitis 12%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Diarrhea 13%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Myalgia 13%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Myoclonus 13%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Micturition disorder 14%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Pharyngitis 14%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Abnormal vision 18%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Nervousness 18%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Weight increase 18%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Acne 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Bronchospasm 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Chills 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Cystitis 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Depersonalization 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Dermatitis 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Dry skin 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Dysphagia 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Dysuria 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Emotional lability 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Epistaxis 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Gastrointestinal disorder 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Irritability 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Localised edema 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Mydriasis 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Thirst 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Urinary retention 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Influence on libido 21%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Dyspepsia 22%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Insomnia 25%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Sweating increased 29%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Agitation 3%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Allergy 3%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Arthralgia 3%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Confusion 3%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Dreaming abnormal 3%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Lacrimation abnormal 3%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Migraine 3%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Pain 3%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Psychosomatic disease 3%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Purpura 3%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Speech disorder 3%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Yawning 3%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Nausea 33%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Fatigue 39%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Chest pain 4%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Fever 4%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Hypertonia 4%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Palpitation 4%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Sleep disorder 4%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Tachycardia 4%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Constipation 47%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Concentration impaired 5%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Depression 5%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Hot flushes 5%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Micturition frequency 5%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Tooth disorder 5%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Headache 52%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Dizziness 54%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Somnolence 54%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Tremor 54%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Back pain 6%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Coughing 6%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Flatulence 6%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Postural hypotension 6%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Pruritus 6%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Sinusitis 6%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Tinnitus 6%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Urinary tract infection 6%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Twitching 7%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Vomiting 7%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Flushing 8%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Rash 8%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Taste perversion 8%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Dry mouth 84%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Anxiety 9%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Memory impairment 9%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Paresthesia 9%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Overview

Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
minor
no
no
no
no
yes
yes
yes
yes (pharmacogenomic study)
Comment: administration of clomipramine to a CYP2C19 intermediate metabolizer resulted in elevated serum trough concentrations
yes
yes (pharmacogenomic study)
Comment: administration of clomipramine to a CYP2D6 intermediate metabolizer resulted in elevated serum trough concentrations
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Letter: Clonazepam in the treatment of drug-induced dyskinesia.
1975 Feb 1
[The influence of clomipramine-induced mania on rapid cycling affective disorder].
1999 Dec 1
[Neuropsychiatric symptoms in preventive antimalarial treatment with mefloquine: apropos of 2 cases].
2000 Jul-Aug
Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs.
2000 Nov
Availability of learned helplessness test as a model of depression compared to a forced swimming test in rats.
2001
Psychogenic excoriation. Clinical features, proposed diagnostic criteria, epidemiology and approaches to treatment.
2001
Involvement of potassium channels in amitriptyline and clomipramine analgesia.
2001
Simultaneous analysis of clozapine, clomipramine and their metabolites by reversed-phase liquid chromatography.
2001 Apr
Reactivity of serotonin in whole blood: relationship with drug response in obsessive-compulsive disorder.
2001 Feb 15
Antidepressants alter cell proliferation in the adult brain in vivo and in neural cultures in vitro.
2001 Jan 5
A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics.
2001 Jul
Neurobiology and clinical pharmacology of obsessive-compulsive disorder.
2001 Jul-Aug
Synthesis and antidepressant activities of some 3,5-diphenyl-2-pyrazolines.
2001 Jun
Diurnal profile of melatonin concentrations in patients with major depression: relationship to the clinical manifestation and antidepressant treatment.
2001 Jun
Comparison of peripheral inhibitory effects of clomipramine with selective serotonin re-uptake inhibitors on contraction of vas deferens: in vitro and in vivo studies.
2001 Jun
Pharmacological treatment of childhood obsessive-compulsive disorder: from theory to practice.
2001 Mar
Effective daily treatment with clomipramine in men with premature ejaculation when 25 mg (as required) is ineffective.
2001 Mar
Long-term effects of clomipramine and fluoxetine on dorsal periaqueductal grey-evoked innate defensive behaviours of the rat.
2001 May
A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression.
2001 May
[A classic antidepressant as an analgesic. Chronic pain under secure control].
2001 May 28
Antidepressant drug treatments induce glial cell line-derived neurotrophic factor (GDNF) synthesis and release in rat C6 glioblastoma cells.
2001 Oct
Clinical predictors of drug response in obsessive-compulsive disorder.
2001 Oct
Taijin kyofusho: a form of social anxiety disorder that responds to serotonin reuptake inhibitors?
2001 Sep
Comment: serotonin syndrome and 5-HT2A antagonism.
2001 Sep
Differential time-course profiles of dopamine release and uptake changes induced by three dopamine uptake inhibitors.
2001 Sep 15
High-performance liquid chromatographic method to screen and quantitate seven selective serotonin reuptake inhibitors in human serum.
2001 Sep 25
Diurnal profile of melatonin secretion in the acute phase of major depression and in remission.
2001 Sep-Oct
Patents

Sample Use Guides

Adults: Treatment should be initiated at a dosage of 25 mg daily and gradually increased, as tolerated, to approximately 100 mg during the first 2 weeks. During initial titration, the drug should be given in divided doses with meals to reduce gastrointestinal side effects. Thereafter, the dosage may be increased gradually over the next several weeks, up to a maximum of 250 mg daily.
Route of Administration: Oral
In Vitro Use Guide
The effect of clomipramine, at concentrations of 10(-7)M to 10(-4)M, was studied in vitro on the uptake of 5-hydroxytryptamine and dopamine uptake in human platelet-rich plasma.
Substance Class Chemical
Created
by admin
on Sat Jun 26 12:54:46 UTC 2021
Edited
by admin
on Sat Jun 26 12:54:46 UTC 2021
Record UNII
NUV44L116D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CLOMIPRAMINE
HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
NSC-169865
Code English
CHLORIMIPRAMINE
Common Name English
CLOMIPRAMINE [MI]
Common Name English
ANAPRAMINE
Common Name English
CLOMIPRAMINE [WHO-DD]
Common Name English
CLOMIPRAMINE [INN]
Common Name English
3-CHLORO-5-(3-(DIMETHYLAMINO)PROPYL)-10,11-DIHYDRO-5H-DIBENZ(B,F)AZEPINE
Systematic Name English
5H-DIBENZ(B,F)AZEPINE-5-PROPANAMINE, 3-CHLORO-10,11-DIHYDRO-N,N-DIMETHYL-
Systematic Name English
CLOMICALM
Brand Name English
3-CHLORO-IMINODIBENZYL
Common Name English
CLOMIPRAMINE [HSDB]
Common Name English
CLOMIPRAMINE [VANDF]
Common Name English
CLOMIPRAMINE [EMA EPAR: VETERINARY]
Common Name English
Classification Tree Code System Code
WHO-ESSENTIAL MEDICINES LIST 24.4
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
NDF-RT N0000175752
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
WHO-ATC N06AA04
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
CFR 21 CFR 520.455
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
NCI_THESAURUS C94727
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
EMA VETERINARY ASSESSMENT REPORTS CLOMICALM (AUTHORISED)
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
WHO-VATC QN06AA04
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
LIVERTOX 223
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C61608
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
PRIMARY
RXCUI
2597
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
PRIMARY RxNorm
EPA CompTox
303-49-1
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
PRIMARY
EVMPD
SUB06725MIG
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
PRIMARY
LACTMED
Clomipramine
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
PRIMARY
ChEMBL
CHEMBL415
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
PRIMARY
DRUG CENTRAL
701
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
PRIMARY
INN
2238
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
PRIMARY
MERCK INDEX
M3648
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
PRIMARY Merck Index
WIKIPEDIA
CLOMIPRAMINE
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
PRIMARY
MESH
D002997
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
PRIMARY
DRUG BANK
DB01242
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
PRIMARY
HSDB
7746
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
PRIMARY
ECHA (EC/EINECS)
206-144-2
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
PRIMARY
PUBCHEM
2801
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
PRIMARY
IUPHAR
2398
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
PRIMARY
FDA UNII
NUV44L116D
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
PRIMARY
CAS
303-49-1
Created by admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> INHIBITOR
IC50
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> SUBSTRATE
Pharmacological action: Tricyclic antidepressant drug (TCA)
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
Metabolizing reaction by CYP2D6: 2- and 8-Hydroxylation
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE ACTIVE -> PARENT
MAJOR
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC